Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy

Higashi, 2002, Association between CYP2C9 genetic variants and anticoagulation‐related outcomes during warfarin therapy, JAMA, 287, 1690, 10.1001/jama.287.13.1690 Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, 352, 2285, 10.1056/NEJMoa044503 Yuan, 2005, A novel functional VKORC1 promoter polymorphism is associated with inter‐individual and inter‐ethnic differences in warfarin sensitivity, Hum Mol Genet, 14, 1745, 10.1093/hmg/ddi180 Gage, 2008, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin, Clin Pharmacol Ther, 84, 326, 10.1038/clpt.2008.10 Schelleman, 2008, Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans, Clin Pharmacol Ther, 84, 332, 10.1038/clpt.2008.101 Carlquist, 2006, Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study, J Thromb Thrombolysis, 22, 191, 10.1007/s11239-006-9030-7 Zhu, 2007, Estimation of Warfarin Maintenance Dose Based on VKORC1 (‐1639 G>A) and CYP2C9 Genotypes, Clin Chem, 53, 1199, 10.1373/clinchem.2006.078139 Klein, 2009, Estimation of the warfarin dose with clinical and pharmacogenetic data, N Engl J Med, 360, 753, 10.1056/NEJMoa0809329 Millican, 2007, Genetic‐based dosing in orthopaedic patients beginning warfarin therapy, Blood, 110, 1511, 10.1182/blood-2007-01-069609 Lenzini, 2008, Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients, J Thromb Haemost, 6, 1655, 10.1111/j.1538-7836.2008.03095.x Lenzini, 2007, Optimal Dose Adjustment in Orthopaedic Patients Beginning Warfarin Therapy, Ann Pharmacother, 41, 1798, 10.1345/aph.1K197 Siguret, 2005, Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen, Am J Med, 118, 137, 10.1016/j.amjmed.2004.07.053 Li, 2009, Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy, Blood, 113, 3925, 10.1182/blood-2008-09-176859 Ridker, 2003, Long‐term, low‐intensity warfarin therapy for the prevention of recurrent venous thromboembolism, N Engl J Med, 348, 1425, 10.1056/NEJMoa035029 Ronaghi, 1998, A sequencing method based on real‐time pyrophosphate, Science, 281, 363, 10.1126/science.281.5375.363 Aquilante, 2004, Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory, Pharmacotherapy, 24, 720, 10.1592/phco.24.8.720.36074 King, 2008, Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose, Am J Clin Path, 129, 876, 10.1309/1E34UAPR06PJ6HML DuBois, 1916, Clinical Calorimetry; a formula to estimate the approximate surface area if height and weight be known, Arch Intern Med, 17, 863, 10.1001/archinte.1916.00080130010002 Rosendaal, 1993, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, 69, 236, 10.1055/s-0038-1651587 Lesko, 2008, The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics, Clin Pharmacol Ther, 84, 301, 10.1038/clpt.2008.133 Caraco, 2008, CYP2C9 genotype‐guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study, Clin Pharmacol Ther, 83, 460, 10.1038/sj.clpt.6100316 Bussey, 2008, Genetic testing for warfarin dosing? Not yet ready for prime time, Pharmacotherapy, 28, 141, 10.1592/phco.28.2.141 Mannucci, 2008, Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No, J Thromb Haemost, 6, 1450, 10.1111/j.1538-7836.2008.03073.x Garcia, 2008, Warfarin and pharmacogenomic testing: the case for restraint, Clin Pharmacol Ther, 84, 303, 10.1038/clpt.2008.131 Ansell, 2008, Pharmacology and management of the Vitamin K Antagonists, Chest, 133, 160S, 10.1378/chest.08-0670 Janes, 2004, Safe introduction of warfarin for thrombotic prophylaxis in atrial fibrillation requiring only a weekly INR, Clin Lab Haematol, 26, 43, 10.1111/j.0141-9854.2003.00579.x Oates, 1998, A new regimen for starting warfarin therapy in out‐patients, Br J Clin Pharmacol, 46, 157, 10.1046/j.1365-2125.1998.00755.x Anderson, 2007, Randomized trial of genotype‐guided versus standard warfarin dosing in patients initiating oral anticoagulation, Circulation, 116, 2563, 10.1161/CIRCULATIONAHA.107.737312 Huang, 2009, Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients, Pharmacogenet Genomics, 19, 226, 10.1097/FPC.0b013e328326e0c7 Schwarz, 2008, Genetic determinants of response to warfarin during initial anticoagulation, N Engl J Med, 358, 999, 10.1056/NEJMoa0708078 Hylek, 2003, Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors, Semin Vasc Med, 3, 271, 10.1055/s-2003-44463 Margaglione, 2000, Genetic modulation of oral anticoagulation with warfarin, Thromb Haemost, 84, 775, 10.1055/s-0037-1614114 Limdi, 2008, Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African‐American and European‐American patients on warfarin, Clin Pharmacol Ther, 83, 312, 10.1038/sj.clpt.6100290